步長製藥(603858.SH):子公司藥品“BC0305膠囊”“BC0306膠囊”臨牀試驗申請獲受理
格隆匯12月20日丨步長製藥(603858.SH)公佈,公司近日獲悉,公司全資子公司山東丹紅製藥有限公司(“山東丹紅”)的“BC0305膠囊”“BC0306膠囊”臨牀試驗申請獲國家藥品監督管理局的受理,並收到《受理通知書》。
BC0305是在配合飲食和運動的基礎上,擬用於改善2型糖尿病患者血糖控制的藥品。根據米內網數據查詢,中國【城市公立,城市社區,縣級公立,鄉鎮衞生】年度銷售趨勢顯示,非胰島素類降血糖藥2018年至2020年銷售額依次為254.1466億元、294.9007億元、261.4678億元。
BC0306主要用於治療非酒精性脂肪肝炎疾病,目前國內外無同靶點上市藥物。
截至公吿日,公司在BC0305項目上投入的研發費用約為2655.03萬元,在BC0306項目上投入的研發費用約為2799.84萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.